Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio:Markers predicting immune-checkpoint inhibitor efficacy and immune-related adverse events

We conducted a comprehensive review of existing prediction models pertaining to the efficacy of immune-checkpoint inhibitor(ICI)and the occurrence of immune-related adverse events(irAEs).The predictive potential of neutrophil-to-lymphocyte ratio(NLR)and platelet-to-lymphocyte ratio(PLR)in determining ICI effectiveness has been extensively investigated,while limited research has been conducted on predicting irAEs.Furthermore,the combined model incor-porating NLR and PLR,either with each other or in conjunction with additional markers such as carcinoembryonic antigen,exhibits superior predictive capabilities compared to individual markers alone.NLR and PLR are promising markers for clinical applications.Forthcoming models ought to incorporate established efficacious models and newly identified ones,thereby constituting a multifactor composite model.Furthermore,efforts should be made to explore effective clinical application approaches that enhance the predictive accuracy and efficiency.

Research Progress of Continuous Nursing for Patients with Chronic Wounds After Discharge

The research status of continuous nursing of patients with chronic wounds is reviewed.Since the research on continuous nursing of chronic wound patients in China is still in the initial stage,if necessary,learn from foreign experience,improve relevant systems,develop corresponding evaluation tools,actively implement telemedicine,and carry out hospital-community linkage models,etc.to provide high-quality nursing services for patients with chronic wounds.

Topical ketotifen treatment for allergic conjunctivitis:a systematic review and Meta-analysis

AIM:To assess the efficacy of ketotifen in treating allergic conjunctivitis.METHODS:A systematic search of systematic reviews and Meta-analyses was conducted on the Pub Med and Web Science of Science until October 2021 to address this knowledge gap.Mean difference with 95%CI and P values were used to assess the efficacy of ketotifen.The heterogeneity(I^(2))was used to evaluate the impact of heterogeneity.RESULTS:Eight randomized controlled trials(RCTs)involving 1589 patients were included in this Meta-analysis.The results revealed that after treating with ketotifen,itching(MD=-0.91,95%CI:-1.63 to-0.20,I^(2)=94%,P=0.01),tearing(MD=-0.40,95%CI:-0.61 to-0.18,I^(2)=75%,P=0.0003)and total signs and symptoms(MD=-0.85,95%CI:-1.12 to-0.58,I2=0,P<0.00001)showed better benefit effect compared to the placebo group.CONCLUSION:Topical ketotifen is an effective treatment for patients with allergic conjunctivitis.

Analysis of the etiologies,treatments and prognoses in children and adolescent vitreous hemorrhage

AIM:To determine the etiologies,treatment modalities and visual outcomes of vitreous hemorrhage(VH;range from birth to 18 y).METHODS:A total of 262 eyes from 210 patients between January 2010 and September 2016 were included.All children underwent an appropriate ocular and systemic examination.Data collected included demographics,clinical manifestations,details of the ocular and systemic examination,management details,final fundus anatomy and visual acuity(VA).RESULTS:The most common etiologies were nontraumatic VH(64.89%),most of which were due to retinopathy of prematurity(ROP;37.10%);while traffic accidents,including 16(21.00%)eyes,was the most common ocular traumas.Surgery,performed in 143(54.58%)eyes,was the most common management modality.The initial mean baseline visual acuity was 2.77±0.21 logarithm of the minimal angle of resolution(log MAR)in children and adolescent with traumatic VH,which was significantly improved to 2.15±1.31 log MAR(P<0.05).CONCLUSION:VH in children and adolescent has a complicated and diverse etiology.ROP is the primary cause of non-traumatic VH,which is the most common etiology.Appropriate treatment of traumatic VH is associated with obvious improvement in visual acuity.The initial VA is one of most important predictors of outcome.